MARKET COMPOSITE
Market TodayThemes and Stocks SummaryThematic Stock SearchDaily Refresh Schedule
ALIM - Alimera Sciences Inc.
$8.07
-0.92(-10.23%)7:54:39 PM 2/25/2021
Alimera Sciences, Inc. is a biopharmaceutical company based in Alpharetta, Georgia that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. The company's main focus is on diseases affecting the back of the eye, or retina. Its main product is ILUVEAN, an fluocinolone acetonide intravitreal implant. Alimera was founded in June 2003 by Dan Myers, Daniel White, Dave Holland and Mark Testerman. Three of the founders were previously part of Ciba Vision Ophthalmics, which was renamed Novartis Ophthalmics following a merger.
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

No summary
Related Topics
leak data

Related Topics

Peers

Stock news

    02/25/2021ALIM
    Alimera Sciences Inc (ALIM) Q4 2020 Earnings Call Transcript

    Joining me from Alimera's leadership team are Rick Eiswirth, President and Chief Executive Officer; and Phil Jones, Chief Financial Officer. During this call, management will be making forward-looking statements, including statements that address Alimera's expectations for future performance or operational results.

    02/24/2021ALIM
    Alimera Sciences Reports Fourth Quarter and 2020 Results

    Fourth Quarter Highlights: Consolidated Net Revenue of $13.8 Million Up 10% vs. Third Quarter of 2020 Consolidated Net Revenue Down 20% vs. Fourth Quarter of 2019 Due to COVID-19 ImpactNet Loss of $(1.0) Million vs. Net Income of $0.5 Million in Fourth Quarter of 2019$1.1 Million Adjusted EBITDA vs. $2.6 Million Adjusted EBITDA in Fourth Quarter of 2019 Year End 2020 Highlights: Consolidated Net Revenue of $50.8 Million International Net Revenue Increased 20% vs. 2019Net Loss of $(5.3) Million v...

    02/18/2021ALIM
    Centric Financial Corporation Announces Earnings for 4th Quarter and Year End 2020

    Centric Financial Corporation ("Centric" or "the Company") (OTC: CFCX), the parent company of Centric Bank ("the Bank"), today reported net income for the fourth quarter and year ended December 31, 2020 of $2.8 million, or $0.33, per basic and diluted share and $9.1 million, or $1.05, per basic and diluted share, respectively.

    02/18/2021ALIM
    Alimera Sciences Continues Global Geographic Expansion With Launch of ILUVIEN in Finland for Both Indications

    ATLANTA, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription ophthalmic pharmaceuticals, announces that ILUVIEN is now available in Finland for diabetic macular edema (DME) and non-infectious uveitis affecting the posterior segment (NIPU), and will be marketed by Alimera and distributed by Nordic Prime. “Finland marks the first of the Nordic countries that we have now...

    02/17/2021ALIM
    Alimera Sciences to Report Fourth Quarter and Full Year 2020 Financial Results on Wednesday, February 24, 2021 and Provide Corporate Update

    Conference Call to be held Thursday, February 25, 2021 at 9:00am Eastern TimeATLANTA, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals for the treatment of retinal diseases, announces today that it will report fourth quarter and full year 2020 financial results on Wednesday, February 24, 2021 after the market close. Management will...

    02/15/2021ALIM
    Alimera Sciences to Present at the Microcap Rodeo Winter Wonderland Conference

    ATLANTA, Feb. 15, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that President and CEO Rick Eiswirth will present at the Microcap Rodeo Winter Wonderland Conference, which will be held from February 16-19, 2021. The presentation will be webcast live on February 16, 2021 at 1:00PM ET and then available for on-demand listening. The...

    02/1/2021ALIM
    Alimera Sciences, Inc. Discusses Its 2021 Global Expansion Strategy with The Stock Day Podcast

    Phoenix, Arizona--(Newsfile Corp. - February 1, 2021) - The Stock Day Podcast welcomed Alimera Sciences, Inc. (NASDAQ: ALIM) ("the Company"), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. President and CEO of the Company, Rick Eiswirth, joined Stock Day host Everett Jolly. Jolly began the interview by asking about the Company's background and current projects. "We are an ophthalmology company, so we're focused on fi...

    01/19/2021ALIM
    Alimera Sciences Announces Preliminary Top-line Results for Fourth Quarter and Full-Year 2020

    ATLANTA, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals for the treatment of retinal diseases, announces preliminary consolidated net revenue for the fourth quarter of 2020 in excess of $13.5 million and annual 2020 consolidated net revenue in excess of $50.5 million. Alimera anticipates that cash on December 31, 2020 will be $11...